Cellyan Biotechnology (HKPD) Debt to Equity (2024 - 2025)
Cellyan Biotechnology (HKPD) reported Debt to Equity of $0.07 for Q3 2025, down 63.49% year-over-year from $0.19 in Q3 2024, and down 81.61% quarter-over-quarter from $0.38 in Q1 2025.
Cellyan Biotechnology (HKPD) Debt to Equity (2024 - 2025) Analysis & Trends
Cellyan Biotechnology (HKPD) has 2 years of Debt to Equity data on file, last reported at $0.07 in Q3 2025.
- Debt to Equity for Q3 2025 came in at $0.07, down 63.49% year-over-year; the trailing twelve-month figure through Sep 2025 was $0.07 (down 63.49% YoY), and the FY2025 annual result was $0.38, up 23.0% from the prior year.
- Debt to Equity slipped to $0.07 in Q3 2025 per HKPD's latest filing, from $0.38 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.38 in Q1 2025 and troughed at $0.07 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Debt/Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Akso Health | 2,315,158.81 Bn | 2,315,158.63 Bn | - | 0.01 |
| 2 | Mckesson | 92.76 Bn | 89.18 Bn | 4.04 Bn | -3.69 |
| 3 | Cencora | 52.82 Bn | 50.83 Bn | 3.59 Bn | 3.45 |
| 4 | Cardinal Health | 52.17 Bn | 48.39 Bn | 2.50 Bn | -3.34 |
| 5 | Henry Schein | 9.19 Bn | 9.71 Bn | 1.07 Bn | 0.72 |
| 6 | Accendra Health | 246.88 Mn | -90.00 Mn | 312.39 Mn | -4.53 |
| 7 | Edap Tms | 161.92 Mn | 146.92 Mn | 8.15 Mn | 1.89 |
| 8 | 111 | 107.47 Mn | 25.61 Mn | 23.58 Mn | -0.26 |
| 9 | Cosmos Health | 9.42 Mn | 7.26 Mn | 1.38 Mn | 0.46 |
| 10 | Cellyan Biotechnology | 5.69 | -2.48 Mn | - | 0.07 |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.07 |
| Mar 31, 2025 | 0.38 |
| Sep 30, 2024 | 0.19 |
| Mar 31, 2024 | 0.31 |